Summary

1. Step 5 — Clinical pathway View details →
   Primary Prevention — Standard pathway

   No CVD, no FH, no diabetes, under 65: standard primary-prevention risk methodology applies.

2. Step 6 — Cardiovascular risk View details →
   Moderate

   Simplified demo scoring (age + smoking + blood pressure + baseline LDL-C) → 3 points → Moderate risk. This is illustrative only, not the licensed ESC calculator.

3. Step 7 — LDL-C target View details →
   <2.6 mmol/L

   Moderate risk → target <2.6 mmol/L.

4. Step 8 — Treatment plan View details →
   Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)

   Maximally tolerated statin + ezetimibe therapy (or documented intolerance) for ≥3 months, still above target — clinically appropriate to consider a PCSK9 inhibitor. This triggers the Swiss Reimbursement Engine.

5. Step 9 — Swiss reimbursement View details →
   Not eligible

   One or more demo reimbursement criteria are not yet met — see missing criteria below.

Demonstration output based on simplified rules — not clinical advice. Generated 07.11.2026 17:14.